About this Research Topic
Accounting for approximately 1% of all new cancers diagnosed globally, bone and soft tissue sarcomas are rare malignancies. Their high heterogeneity with more than a hundred subtypes has further undermined the development of robust, evidence-based treatment strategies, and our therapeutic approach is hardly patient-specific or widely standardized. Therefore, generating the appropriate evidence of high quality for the diagnosis and treatment is challenging.
Although surgery is the mainstay treatment in most cases, radiotherapy and chemotherapy are included in the current clinical practice of bone and soft tissue sarcomas management. In the last decades, molecular targeting agents have shown favourable performance in some specific types of these sarcomas and even in some aggressive benign tumours.
The purpose of this research topic is to provide a platform for researchers who work on bone and soft tissue tumours to explore more effective pharmacotherapeutics with an emphasis on molecular targeting agents.
We welcome submissions of Original Research, Brief Research Reports, Clinical Trial Articles, Review, Systematic Review, Case Report, , and General Commentary. Subtopics of interest include but are not limited to:
- Pharmacotherapeutics involving molecular targeting inhibitors or other systemic therapy agents for bone and soft tissue tumours
- Molecular mechanisms, signalling pathways, and new targets that may stimulate therapeutic advances in bone and soft tissue tumours
Although surgery is the mainstay treatment in most cases, radiotherapy and chemotherapy are included in the current clinical practice of bone and soft tissue sarcomas management. In the last decades, molecular targeting agents have shown favourable performance in some specific types of these sarcomas and even in some aggressive benign tumours.
The purpose of this research topic is to provide a platform for researchers who work on bone and soft tissue tumours to explore more effective pharmacotherapeutics with an emphasis on molecular targeting agents.
We welcome submissions of Original Research, Brief Research Reports, Clinical Trial Articles, Review, Systematic Review, Case Report, , and General Commentary. Subtopics of interest include but are not limited to:
- Pharmacotherapeutics involving molecular targeting inhibitors or other systemic therapy agents for bone and soft tissue tumours
- Molecular mechanisms, signalling pathways, and new targets that may stimulate therapeutic advances in bone and soft tissue tumours
Keywords: Bone oncology, soft tissue tumour, chemotherapy, systemic therapy, molecular targeting inhibitor, individualized therapy, combined chemotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
